TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia.
Journal
Leukemia
ISSN: 1476-5551
Titre abrégé: Leukemia
Pays: England
ID NLM: 8704895
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
13
05
2019
accepted:
03
07
2019
revised:
18
06
2019
pubmed:
25
8
2019
medline:
2
6
2020
entrez:
25
8
2019
Statut:
ppublish
Résumé
Abnormal karyotypes are common in cancer cells and frequently observed in acute myeloid leukemia (AML), in which complex karyotype aberrations are associated with poor prognosis. How exactly abnormal karyotypes arise and are propagated in AML is unclear. TP53 mutations and deletions are frequent in complex karyotype AML, suggesting a role of TP53 alterations in the development of chromosome abnormalities. Here, we generated isogenic TP53-knockout versions of the euploid AML cell line EEB to investigate the impact of TP53 on karyotype stability. We show that chromosome abnormalities spontaneously arise in TP53-deficient cells. Numerical aneuploidy could, to some extent, be propagated in a TP53-proficient setting, indicating that it does not necessarily trigger TP53 activation. In contrast, tolerance to structural chromosome aberrations was almost entirely restricted to TP53-knockout clones, all of which were able to continue proliferation in the presence of damaged DNA. Mechanistically, as a source of chromosome aberrations, limited numerical but not structural chromosomal instability was tolerated by TP53-wildtype cells. In contrast, structural instability was found only in TP53-knockout cells. Together, in myeloid cells TP53 loss allows for the development of complex karyotype aberrations and karyotype heterogeneity by perpetuation of chromosome segregation errors.
Identifiants
pubmed: 31444400
doi: 10.1038/s41375-019-0550-5
pii: 10.1038/s41375-019-0550-5
doi:
Substances chimiques
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2619-2627Références
Davoli T, Xu AW, Mengwasser KE, Sack LM, Yoon JC, Park PJ, et al. Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. Cell. 2013;155:948–62.
doi: 10.1016/j.cell.2013.10.011
Grimwade BD, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–33.
doi: 10.1182/blood.V92.7.2322
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukaemia: determination of prognostic significance of rarer recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the UK Medical Research Council trials. Blood. 2010;116:354–65.
doi: 10.1182/blood-2009-11-254441
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the WHO classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.
doi: 10.1182/blood-2009-03-209262
Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1312–20.
doi: 10.1182/blood.V98.5.1312
Haferlach C, Dicker F, Herholz H, Schnittger S, Kern W, Haferlach T. Mutations of the TP53 gene in acute myeloid leukemia are strongly associated with a complex aberrant karyotype. Leukemia. 2008;22:1539–41.
doi: 10.1038/leu.2008.143
Rücker FG, Schlenk RF, Bullinger L, Kayser S, Teleanu V, Kett H, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119:2114–21.
doi: 10.1182/blood-2011-08-375758
Stengel A, Kern W, Haferlach T, Meggendorfer M, Fasan A, Haferlach C. The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases. Leukemia. 2017;31:705–11.
doi: 10.1038/leu.2016.263
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.
doi: 10.1056/NEJMoa1516192
Bochtler T, Stölzel F, Heilig CE, Kunz C, Mohr B, Jauch A, et al. Clonal heterogeneity as detected by metaphase karyotyping is an indicator of poor prognosis in acute myeloid leukemia. J Clin Oncol. 2013;31:3898–905.
doi: 10.1200/JCO.2013.50.7921
Thompson SL, Compton DA. Proliferation of aneuploid human cells is limited by a p53-dependent mechanism. J Cell Biol. 2010;188:369–81.
doi: 10.1083/jcb.200905057
Bunz F, Fauth C, Speicher MR, Dutriaux A, Sedivy JM, Kinzler KW, et al. Targeted inactivation of p53 in human cells does not result in aneuploidy. Cancer Res. 2002;62:1129–33.
pubmed: 11861393
Soto M, Raaijmakers JA, Bakker B, Spierings DCJ, Lansdorp PM, Foijer F, et al. p53 prohibits propagation of chromosome segregation errors that produce structural aneuploidies. Cell Rep. 2017;19:2423–31.
doi: 10.1016/j.celrep.2017.05.055
Santaguida S, Richardson A, Iyer DR, M’Saad O, Zasadil L, Knouse KA, et al. Chromosome mis-segregation generates cell-cycle-arrested cells with complex karyotypes that are eliminated by the immune system. Dev Cell. 2017;41:638–51.
doi: 10.1016/j.devcel.2017.05.022
Rehen SK, McConnell MJ, Kaushal D, Kingsbury MA, Yang AH, Chun J. Chromosomal variation in neurons of the developing and adult mammalian nervous system. Proc Natl Acad Sci USA. 2001;98:13361–6.
doi: 10.1073/pnas.231487398
Rehen SK, Yung YC, McCreight MP, Kaushal D, Yang AH, Almeida BS, et al. Constitutional aneuploidy in the normal human brain. J Neurosci. 2005;25:2176–80.
doi: 10.1523/JNEUROSCI.4560-04.2005
Laurie CC, Laurie CA, Rice K, Doheny KF, Zelnick LR, McHugh CP, et al. Detectable clonal mosaicism from birth to old age and its relationship to cancer. Nat Genet. 2012;44:642–50.
doi: 10.1038/ng.2271
Forsberg LA, Rasi C, Malmqvist N, Davies H, Pasupulati S, Pakalapati G, et al. Mosaic loss of chromosome Y in peripheral blood is associated with shorter survival and higher risk of cancer. Nat Genet. 2014;46:624–8.
doi: 10.1038/ng.2966
Gronroos E, López-García C. Tolerance of chromosomal instability in cancer: mechanisms and therapeutic opportunities. Cancer Res. 2018;78:6529–35.
doi: 10.1158/0008-5472.CAN-18-1958
Kawano-Yamamoto C, Muroi K, Nagatsuka Y, Higuchi M, Kikuchi S, Nagai T, et al. Establishment and characterization of a new erythroblastic leukemia cell line, EEB: phosphatidylglucoside-mediated erythroid differentiation and apoptosis. Leuk Res. 2006;30:829–39.
doi: 10.1016/j.leukres.2005.10.021
Ran FA, Hsu PD, Wright J, Agarwala V, Scott D, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013;8:2281–308.
doi: 10.1038/nprot.2013.143
Haeussler M, Schönig K, Eckert H, Eschstruth A, Mianné J, Renaud JB, et al. Evaluation of off-target and on-target scoring algorithms and integration into the guide RNA selection tool CRISPOR. Genome Biol. 2016;17:148.
doi: 10.1186/s13059-016-1012-2
Geigl JB, Uhrig S, Speicher MR. Multiplexfluorescence in situ hybridization for chromosome karyotyping. Nat Protoc. 2006;1:1172–84.
doi: 10.1038/nprot.2006.160
Lengauer C, Kinzler K, Vogelstein B. Genetic instability in colorectal cancers. Nature. 1997;10:623–7.
doi: 10.1038/386623a0
Bayani J, Paderova J, Murphy J, Rosen B, Zielenska M, Squire JA. Distinct patterns of structural and numerical chromosomal instability characterize sporadic ovarian cancer. Neoplasia. 2008;10:1057–65.
doi: 10.1593/neo.08584
Thomas J, Kornberg RD. An octamer of histones in chromatin and free in solution. Proc Natl Acad Sci USA. 1975;72:2626–30.
doi: 10.1073/pnas.72.7.2626
Uetake Y, Sluder G. Prolonged prometaphase blocks daughter cell proliferation despite normal completion of mitosis. Curr Biol. 2010;20:1666–71.
doi: 10.1016/j.cub.2010.08.018
Li M, Fang X, Baker DJ, Guo L, Gao X, Wei Z, et al. The ATM-p53 pathway suppresses aneuploidy-induced tumorigenesis. Proc Natl Acad Sci USA. 2010;107:14188–93.
doi: 10.1073/pnas.1005960107
Janssen A, van der Burg M, Szuhai K, Kops GJ, Medema RH. Chromosome segregation errors as a cause of DNA damage and Structural Chromosome Aberrations. Science. 2011;333:1895–8.
doi: 10.1126/science.1210214
Fenaux P, Preudhomme C, Quiquandon I, Jonveaux P, Laï JL, Vanrumbeke M, et al. Mutations of the P53 gene in acute myeloid leukaemia. Br J Haematol. 1992;80:178–83.
doi: 10.1111/j.1365-2141.1992.tb08897.x
Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, et al. FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood. 2001;97:3589–95.
doi: 10.1182/blood.V97.11.3589
Seifert H, Mohr B, Thiede C, Oelschlägel U, Schäkel U, Illmer T, et al. The prognostic impact of17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia. 2009;23:656–63.
doi: 10.1038/leu.2008.375
Bowen D, Groves MJ, Burnett AK, Patel Y, Allen C, Green C, et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia. 2009;23:203–6.
doi: 10.1038/leu.2008.173
Santaguida S, Amon A. Short- and long-term effects of chromosome mis-segregation and aneuploidy. Nat Rev Mol Cell Biol. 2015;16:473–85.
doi: 10.1038/nrm4025